Soligenix Reports Positive Phase 2a Results for SGX945 in Behçet's Disease Treatment

Soligenix Inc. announced that results from its Phase 2a proof-of-concept study evaluating SGX945 for the treatment of aphthous ulcers associated with Behçet's Disease have been published in Rheumatology (Oxford), reporting beneficial effects in seven of eight patients with sustained improvement through a four-week follow-up period after treatment ended. The company said outcomes for SGX945, including reductions in oral ulcers and pain and favorable area under the curve measurements, were comparable to those reported in a Phase 3 study of apremilast (Otezla(R)), despite SGX945 dosing stopping at Week 4 while apremilast required continuous administration.

This distinction matters because it suggests SGX945 may offer similar therapeutic benefits with potentially fewer dosing requirements than existing treatments, which could improve patient compliance and quality of life. Behçet's Disease is a rare, chronic inflammatory disorder characterized by recurrent oral ulcers and other symptoms, representing an area of significant unmet medical need where new treatment options are valuable. The sustained improvement observed after treatment cessation indicates SGX945 may have lasting effects beyond the administration period.

Soligenix noted SGX945 was well tolerated with no treatment-related adverse events observed, an important consideration for any new therapeutic candidate. The company said it plans to pursue reformulation to enable home-based subcutaneous administration, which could further enhance patient convenience and accessibility. Additionally, Soligenix is expanding development of dusquetide across additional innate immune-related inflammatory conditions and engaging regulators on a follow-on clinical study for this area of unmet medical need.

The publication of these results in a peer-reviewed journal like Rheumatology (Oxford) lends credibility to the findings and allows for broader scientific scrutiny and discussion within the medical community. For more information about Soligenix's developments, visit https://ibn.fm/SNGX. The positive Phase 2a data supports continued investigation of SGX945 as a potential treatment option for Behçet's Disease patients who may benefit from alternatives to current therapies requiring continuous administration.